Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NAXIVA- Phase II Neoadjuvant Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Clear Cell Renal Cell Cancer With Venous Invasion

NCT03494816 is registered in ClinicalTrials.gov with Scottish Clinical Trials Research Unit as lead sponsor.

NCT NCT03494816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03494816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NAXIVA- Phase II Neoadjuvant Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Clear Cell Renal Cell Cancer With Venous Invasion
Lead sponsor
Scottish Clinical Trials Research Unit
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2017
Completion date
June 10, 2020
Enrollment
24 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma, non-metastatic renal cell carcinoma, renal cell carcinoma